Supplementary Figure 5 from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis

2024-04-03

<p>Supplementary figure 5 shows that there were no significant differences in any (A) or curative treatment (B) receipt between Asian and White patients.</p>

Supplementary Figure 2 from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis

2024-04-03

<p>Supplementary figure 2 shows that the pooled proportion for any HCC treatment rate among early-stage HCC patients is 59.6%.</p>

Supplementary Figure 2 from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis

2024-04-03

<p>Supplementary figure 2 shows that the pooled proportion for any HCC treatment rate among early-stage HCC patients is 59.6%.</p>

Data from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis

2024-04-03

<div>AbstractBackground:<p>Racial and ethnic disparities in hepatocellular carcinoma (HCC) prognosis exist, partly related to differential failures along the cancer care continuum. We characterized racial and ethnic disparities in treatment receipt among patients with HCC in the United States.</p>Methods:<p>We searched Medline, Embase, and CINAHL databases to identify studies published between January 2012 and March 2022 reporting HCC treatment receipt among adult patients with HCC, stratified by race or ethnicity. We calculated pooled odds ratios for HCC treatment using random effects models.</p>Results:<p>We identified 15 studies with 320,686 patients (65.8% White, 13.9% Black, 10.4% Asian, and 8.5% Hispanic). Overall, 33.2% of HCC patients underwent any treatment, and 22.7% underwent curative treatment. Compared with White patients, Black patients had lower odds of any treatment (OR 0.67, 95% CI 0.55–0.81) and curative treatment (OR 0.74, 95% CI 0.71–0.78). Similarly, Hispanic patients had lower pooled odds of curative treatment (OR 0.79, 95% CI 0.73–0.84).</p>Conclusions:<p>There were significant racial and ethnic disparities in HCC treatment receipt, with Black patients having lower odds of receiving any and curative treatment while Hispanic patients having lower odds of curative treatment.</p>Impact:<p>Racial and ethnic differences in treatment receipt serve as an intervention target to reduce disparities in HCC prognosis.</p></div>

Supplementary Figure 3 from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis

2024-04-03

<p>Supplementary figure 3 shows that the pooled proportion for curative HCC treatment among early-stage HCC patients is 51.4%.</p>

Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis

Cancer Epidemiology Biomarkers & Prevention · 2024-01-22 · 12 citations

BACKGROUND: Racial and ethnic disparities in hepatocellular carcinoma (HCC) prognosis exist, partly related to differential failures along the cancer care continuum. We characterized racial and ethnic disparities in treatment receipt among patients with HCC in the United States. METHODS: We searched Medline, Embase, and CINAHL databases to identify studies published between January 2012 and March 2022 reporting HCC treatment receipt among adult patients with HCC, stratified by race or ethnicity. We calculated pooled odds ratios for HCC treatment using random effects models. RESULTS: We identified 15 studies with 320,686 patients (65.8% White, 13.9% Black, 10.4% Asian, and 8.5% Hispanic). Overall, 33.2% of HCC patients underwent any treatment, and 22.7% underwent curative treatment. Compared with White patients, Black patients had lower odds of any treatment (OR 0.67, 95% CI 0.55-0.81) and curative treatment (OR 0.74, 95% CI 0.71-0.78). Similarly, Hispanic patients had lower pooled odds of curative treatment (OR 0.79, 95% CI 0.73-0.84). CONCLUSIONS: There were significant racial and ethnic disparities in HCC treatment receipt, with Black patients having lower odds of receiving any and curative treatment while Hispanic patients having lower odds of curative treatment. IMPACT: Racial and ethnic differences in treatment receipt serve as an intervention target to reduce disparities in HCC prognosis.

Supplementary Figure 4 from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis

2024-04-03

<p>Supplementary figure 4 shows that Black patients with early-stage HCC are significantly less likely to undergo curative treatment than White patients (pooled OR 0.63, 95%CI 0.47 – 0.84).</p>

Supplementary Table 1 from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis

2024-04-03

<p>MOOSE Checklist</p>

Supplementary Figure 5 from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis

2024-04-03

<p>Supplementary figure 5 shows that there were no significant differences in any (A) or curative treatment (B) receipt between Asian and White patients.</p>

Supplementary Table 2 from Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis

2024-04-03

<p>SES and geographic covariates included in the multivariable analysis of receipt of HCC treatment.</p>